10-Q: Advanced Biomed Inc. Reports Q3 2025 Results, Highlights IPO and Ongoing R&D

Advanced Biomed Inc. reports its Q3 2025 results, highlighting its recent IPO and ongoing research and development efforts in microfluidic biochip technology for oncology.

Summary

• Advanced Biomed Inc., a Nevada-based holding company, released its unaudited interim condensed consolidated financial statements for the quarter ended March 31, 2025.
• The company completed its initial public offering (IPO) on March 7, 2025, issuing 1,640,000 shares at $4.00 per share, raising gross proceeds of $6.56 million.
• Advanced Biomed is focused on developing microfluidic biochip technologies for early cancer screening, diagnosis, and treatment.
• The company is planning to begin clinical research for its A+LCGuard Lung Cancer Early Screening Kit by the end of June 2025, with completion anticipated within six months of October 2025.
• For the nine-month period ended March 31, 2025, the company reported a net loss of $2,557,358 and net cash outflows from operating activities of $4,281,093.
• The company's ability to continue as a going concern depends on its ability to develop, register, and obtain regulatory approval for its products.
• As of March 31, 2025, the company had a working capital surplus of $3,617,805 and cash and cash equivalents of $5,184,100.
• The company is pursuing regulatory clearances in China and plans to expand to North America and Europe.
• The company expects to be in a state of continuous loss for the next two to three years.

Sentiment

Score: 4

Explanation: The sentiment is neutral to slightly negative. The company successfully completed its IPO, but it is still operating at a loss and faces significant challenges in obtaining regulatory approvals and achieving profitability. The auditor's concern about the company's ability to continue as a going concern adds to the negative sentiment.

Positives

• The successful completion of the IPO provides the company with additional capital to fund its operations and research and development efforts.
• Clearance of A+Pre and AC-1000 in China represents a significant regulatory milestone.
• The company has a working capital surplus of $3,617,805 as of March 31, 2025.
• The company has cash and cash equivalents of $5,184,100 as of March 31, 2025.

Negatives

• The company reported a net loss of $2,557,358 for the nine-month period ended March 31, 2025.
• The company had net cash outflows from operating activities of $4,281,093 for the nine-month period ended March 31, 2025.
• The company's auditors have raised substantial doubt about its ability to continue as a going concern.
• The company expects to be in a state of continuous loss for the next two to three years.

Risks

• The company's ability to continue as a going concern is dependent on obtaining regulatory approvals and generating positive operating cash flows.
• Delays in obtaining ethical approval or recruiting participants could prevent the clinical research from being completed on schedule.
• The company faces risks related to political, economic, and legal environments in Taiwan and mainland China.
• The company is exposed to foreign currency exchange rate fluctuations.
• The company has not commenced sales of its products nor have any revenue-generating products and does not expect sales of revenue-generating product candidates until it has completed clinical development, submitted regulatory filings, and received applicable regulatory approvals for candidate products.

Future Outlook

The company expects to be in a state of continuous loss for the next two to three years and is focused on obtaining regulatory approvals and expanding its operations to North America and Europe.

Management Comments

• Management has commenced a strategy to raise debt from the Company's related party.
• Management has commenced a strategy to raise debt and equity, including financial supports from the Company's related party and stockholders as well as third parties, which will enable that we have sufficient working capital for our requirements for at least the next 4 months from the date of this report, in the absence of unforeseen circumstances, taking into account the cash and financial resources presently available to us.

Industry Context

The company operates in the competitive field of oncology diagnostics and therapeutics, focusing on early cancer screening and personalized medicine. The company is pursuing regulatory clearances in China and plans to expand to North America and Europe.

Comparison to Industry Standards

• The company's financial performance is not directly comparable to established industry leaders due to its early stage of development and lack of revenue generation.
• The company's focus on microfluidic biochip technology aligns with the broader industry trend towards miniaturization and automation in diagnostics.
• The company's planned expansion into North America and Europe reflects the global nature of the oncology market.

Related Party Transactions

• Advanced Biomed Inc. (Taiwan) entered into an unsecured, interest-free loan to Yi Lu, Ph.D. amounting to NTD 3,578,212 (approximately US$107,810) for general working capital in January 2023.
• Advanced Biomed Inc.(HK) entered into one unsecured, interest-free loan to Hung To Pau, Ph.D. amounting to US$200,000 for general working capital in July 2024.
• Shanghai Sglcell Biotech Co., Ltd entered into three unsecured, interest-free loans to Hung To Pau, Ph.D. amounting to RMB122,566 (approximately US$16,890), RMB121,681 (approximately US$16,768) and RMB76,000 (approximately US$10,473) for general working capital in October 2024, November 2024 and December 2024.
• Advanced Biomed Inc.(Taiwan) entered into four unsecured, interest-free loans to Well Fancy Development Ltd amounting to NTD 5,740,600 (approximately US$172,962), NTD 1,911,944 (approximately US$57,606), NTD 1,906,840 (approximately US$57,452), NTD 3,121,500 (approximately US$94,049), NTD 1,798,060 (approximately US$54,175), NTD 1,291,552 (approximately US$38,914) and NTD 455,992 (approximately US$13,739) for general working capital in July 2024, October 2024, November 2024, December 2024, January 2025, February 2025 and March 2025.
• Advanced Biomed Inc. entered into one unsecured, interest-free loan to Well Fancy Development Ltd amounting to US$119,975 and US$155,000 for general working capital in November 2024 and March 2025.
• Shanghai Sglcell Biotech Co., Ltd entered into nine unsecured, interest-free loans to Shanghai Junfu Electronic Technology Co., Ltd. amounting to RMB500,000 (approximately US$68,902) in April 2023, May 2023, June 2023 and September 2023, respectively, and RMB700,000 (approximately US$96,462), RMB1,500,000 (approximately US$206,706), RMB700,000 (approximately US$96,462) and RMB650,000 (approximately US$89,572) in January 2024, March 2024, June 2024 and October 2024, respectively, for general working capital.

Stakeholder Impact

• Shareholders: The company's IPO provides an opportunity for investors to participate in its growth, but the company's losses and going concern uncertainty pose risks.
• Employees: The company's expansion plans could create new job opportunities, but its financial challenges could impact job security.
• Customers: The company's products have the potential to improve cancer diagnostics and treatment, but regulatory hurdles and clinical trial results will determine their availability.
• Suppliers: The company's research and development activities and expansion plans could create new business opportunities for suppliers.
• Creditors: The company's ability to repay its debts is dependent on its ability to generate positive cash flows and obtain additional financing.

Next Steps

• Begin clinical research for A+LCGuard Lung Cancer Early Screening Kit by the end of June 2025.
• Pursue regulatory clearances for products in China.
• Establish subsidiaries in the United States and Europe.
• Conduct localized management and operations in accordance with European regulations.
• Start the localized registration of IVD products in Europe in 2025.
• Complete site selection and personnel recruitment in the United States by the end of 2025.

Key Dates

Keywords

microfluidic biochip, oncology, cancer, IPO, clinical trials, regulatory approval, research and development, Advanced Biomed